Expert Insight View All

The potential new first-line mNSCLC treatment regardless of PD-L1: Durvalumab + tremelimumab + chemotherapy improved survival

Over the past decades, treatment options in advanced non-small cell lung cancer (NSCLC) patients without oncogenic drivers have been limited to cytotoxic chemotherapies with poor survival outcomes.1 Although patients’ overall survival (OS) has been prolonged with the current standard of care (SoC) (i.e. pembrolizumab with or without chemotherapy) in recent years, the clinical outcomes are still suboptimal.2,3 Dual immunotherapy, which brought substantial survival improvements across multiple malignancies such as advanced melanoma, sheds light on the further advance of metastatic NSCLC (without driver mutations) management.4 The combination of nivolumab (NIVO) and ipilimumab (IPI) with or without chemotherapy has demonstrated superior survival benefits in these patients, leading to the regulatory approval from the United States (US) Food and Drug Administration (FDA).5,6 More recently, the efficacy of durvalumab and tremelimumab plus chemotherapy (D + T + CT) in treatment-naïve metastatic NSCLC patients has also been evaluated in the POSEIDON trial.7 In a webinar organized by the Hong Kong Precision Oncology Society, Dr. Melissa L. Johnson presented the encouraging data from POSEIDON and discussed the latest advances of immunotherapy in metastatic NSCLC. Dr. Au, Siu-Kie Joseph also shared his expert insights on the new POSEIDON data and discussed their impacts on the local clinical practice in an interview with Omnihealth Practice.

03 May 2022

Dr. Melissa L. Johnson

Lung Cancer Research Program,
Sarah Cannon/Tennessee Oncology PLLC,
Nashville, United States


Dr. Au, Siu-Kie Joseph

Head and Consultant Clinical Oncologist,
Hong Kong Adventist Hospital Oncology Centre
Hong Kong Lung Cancer Study Group
Hong Kong Precision Oncology Society

Meeting Highlight View All

Adopting durvalumab consolidation therapy: A breakthrough for non-small cell lung cancer treatment


Dr. Lee, Ho-Fun Victor

Clinical Associate Professor,
Department of Clinical Oncology,
The University of Hong Kong


Dr. Chan, Siu-Hong Oscar

Specialist in Clinical Oncology,
Hong Kong Integrated Oncology Centre


Dr. Nyaw, Shi-Feng Jonathan

Specialist in Clinical Oncology,
Department of Clinical Oncology,
Tuen Mun Hospital

Research Spotlight View All

Sketching the roadmap for Asian lung cancer management: Expert consensus on lung cancer screening practices in Asian populations

Lung cancer (LC) is regarded as the most lethal form of cancer in Asia.1 In 2020, the World Health Organization (WHO) ’s Global Cancer Observatory (GLOBOCAN) estimated that 60% of global LC cases and 62% of global LC-related mortality were from Asian countries.1

16 Nov 2023

Dr. Lam, Chi-Leung David

Chief of Respiratory Medicine Division Clinical Associate Professor, Department of Medicine, 
Li Ka Shing Faculty of Medicine,
The University of Hong Kong 

J Thorac Oncol. 2023.

Lam D. C. L., Liam C. K., Andarini S., Park S., Tan D. S. W., Singh N., Jang S. H., Vardhanabhuti V., Ramos A. B., Nakayama T., Nhung N. V., Ashizawa K.,  Chang Y. C., Tscheikuna J., Van C. C., Chan W. Y., Lai Y. H., Yang P. C. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023;18(10):1303-1322.

Infographics View All

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023